Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8268791 | UPSHER SMITH LABS | Alkylglycoside compositions for drug administration |
May, 2026
(2 years from now) | |
US8440631 | UPSHER SMITH LABS | Compositions for drug administration |
May, 2026
(2 years from now) | |
US9283280 | UPSHER SMITH LABS | Compositions for drug administration |
May, 2026
(2 years from now) | |
US9610280 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
US9974770 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
US10603305 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
US11337962 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
US9211282 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jul, 2031
(7 years from now) |
Tosymra is owned by Upsher Smith Labs.
Tosymra contains Sumatriptan.
Tosymra has a total of 8 drug patents out of which 0 drug patents have expired.
Tosymra was authorised for market use on 25 January, 2019.
Tosymra is available in spray;nasal dosage forms.
Tosymra can be used as acute treatment of migraine.
The generics of Tosymra are possible to be released after 19 July, 2031.
Drugs and Companies using SUMATRIPTAN ingredient
Market Authorisation Date: 25 January, 2019
Treatment: Acute treatment of migraine
Dosage: SPRAY;NASAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic